Study on EGFR tyrosine kinase inhibitor drug Osimertinib resistance in EGFR mutant NSCLC for analysis of immunohistochemistory of tumor tissues.
Not Applicable
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000037294
- Lead Sponsor
- Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ovel resistant mechanism to Osimertinib
- Secondary Outcome Measures
Name Time Method